

Potent GH20 N-Acetyl- β -D-hexosaminidase inhibitors: N-Substituted 4-acetamido-5-amino- 1-hydroxymethyl- cyclopentanediols

Patrick Weber¹, Seyed A. Nasseri², Bettina M. Pabst³, Ana Torvisco⁴, Philipp Müller⁴, Eduard Paschke³, Marion Tschernutter³, Werner Windischhofer³, Stephen G. Withers², Tanja M. Wrodnigg¹, Arnold E. Stütz^{1*}

¹ Glycogroup, Institute of Organic Chemistry, Graz University of Technology, Stremayrgasse 9, A-8010 Graz, Austria; patrick.weber@tugraz.at (P.W.); t.wrodnigg@tugraz.at (T.M.W.)


² Chemistry Department, University of British Columbia, 2036 Main Mall, Vancouver, BC V6T 1Z1, Canada; snasseri@chem.ubc.ca (S.A.N.); withers@chem.ubc.ca (S.G.W.)

³ Laboratory of Metabolic Diseases, Department of Pediatrics, MedUni Graz, Auenbruggerplatz 30, A-8036 Graz, Austria; bettina.pabst@medunigraz.at (B.M.P.); eduard.paschke@inode.at (E.P.); marion.tschernutter@medunigraz.at (M.T.); werner.windischhofer@medunigraz.at (W.W.)


⁴ Institute of Inorganic Chemistry, Graz University of Technology, Stremayrgasse 9, A-8010 Graz, Austria; ana.torviscogomez@tugraz.at (A.T.); philipp.mueller@tugraz.at (P.M.)

(3a*R*,3b*S*,6a*R*,7*R*,7a*R*)-Hexahydro-5,5-dimethyl-1-phenyl-1*H*-[1,3]dioxolo[3,4]cyclopent[1,2-*c*]isoxazol-7-ol or 1-*L*-(1,2,3,4,5)-1¹,2¹-anhydro-1-hydroxymethyl-2-(*N*-hydroxy)benzylamino-4,5-*O*-isopropylidene-3,4,5-cyclopentanetriol 14


¹H NMR (300 MHz, CDCl₃): compound 14




¹³C NMR (75.5 MHz, CDCl₃): compound 14



COSY (CDCl_3): compound 14




HSQC (CDCl_3): compound 14




(3a*R*,3b*S*,6a*R*,7*S*,7a*R*)-Hexahydro-7-azido-5,5-dimethyl-1-phenyl-1*H*-[1,3]dioxolo[3,4]cyclopent[1,2-c]isoxazol or 1-L-(1,2,4,5/3)-1¹,2¹-anhydro-3-azido-1-hydroxymethyl-2-(*N*-hydroxy)benzylamino-4,5-*O*-isopropylidene-4,5-cyclopentanediol 16


¹H NMR (300 MHz, CDCl₃): compound 16




¹³C NMR (75.5 MHz, CDCl₃): compound 16



COSY (CDCl_3): compound 16




HSQC (CDCl_3): compound 16




(3a*R*,3b*S*,6a*R*,7*S*,7a*R*)-Hexahydro-7-acetamido-5,5-dimethyl-1-phenyl-1*H*-[1,3]dioxolo[3,4]cyclopent[1,2-c]isoxazol or 1-L-(1,2,4,5/3)-1¹,2¹-anhydro-3-acetamido-1-hydroxymethyl-2-(*N*-hydroxy)benzylamino-4,5-*O*-isopropylidene-4,5-cyclopentanediol **18**


¹H NMR (300 MHz, CDCl₃): compound **18**




¹³C NMR (75.5 MHz, CDCl₃): compound **18**



COSY (CDCl₃): compound 18




HSQC (CDCl₃): compound 18




(3a*S*,4*R*,5*R*,6*S*,6a*R*)-5-Amino-tetrahydro-6-acetamido-2,2-dimethyl-4*H*-cyclopenta-1,3-dioxole-4-methanol or 1-L-(1,2,4,5/3)-3-acetamido-2-amino-1-hydroxymethyl-4,5-O-isopropylidene-4,5-cyclopentanediol 19


¹H NMR (300 MHz, CDCl₃): compound **19**




¹³C NMR (75.5 MHz, CDCl₃): compound **19**



COSY (CDCl_3): compound 19




HSQC (CDCl_3): compound 19




(1*S*,2*R*,3*S*,4*R*,5*R*)-3-Acetamido-4-amino-5-hydroxymethylcyclopentanetriol or “1-amino-2-acetamido-2-deoxy- β -D-galacto-cyclopentane” 20


^1H NMR (500 MHz, D₂O): compound 20




^{13}C NMR (125.9 MHz, D₂O): compound 20



COSY (D₂O): compound 20




HSQC (D₂O): compound 20




**(1*S*,2*R*,3*S*,4*R*,5*R*)-*N*-(1-Hexyl)-3-acetamido-4-amino-5-hydroxymethylcyclopentanetriol or
“2-acetamido-2-deoxy-1-(hexyl)amino- β -D-galacto-cyclopentane” 21**


^1H NMR (500 MHz, CD₃OD): compound 21




^{13}C NMR (125.9 MHz, CD₃OD): compound 21



COSY (CD₃OD): compound 21




HSQC (CD₃OD): compound 21




(1*S*,2*R*,3*S*,4*R*,5*R*)-*N*-(Methoxycarbonyl)pentyl-3-acetamido-4-amino-5-hydroxymethyl-cyclopentanetriol or “2-acetamido-2-deoxy-1-(methoxycarbonylhexyl)amino- β -D-galacto-cyclopentane” 22


^1H NMR (300 MHz, CD₃OD): compound 22




^{13}C NMR (75.5 MHz, CD₃OD): compound 22



COSY (CD₃OD): compound 22




HSQC (CD₃OD): compound 22




(1*S*,2*R*,3*S*,4*R*,5*R*)-*N*-(5-*C*-cyano)pentyl-3-acetamido-4-amino-5-hydroxymethyl-cyclopentanetriol or “2-acetamido-2-deoxy-1-(5-*C*-cyano)pentylamino- β -D-galacto-cyclopentane” 23


^1H NMR (300 MHz, CD₃OD): compound 23




^{13}C NMR (75.5 MHz, CD₃OD): compound 23



COSY (CD₃OD): compound 23




HSQC (CD₃OD): compound 23




(1*S*,2*R*,3*S*,4*R*,5*R*)-*N*-(6-amino)hexyl-3-acetamido-4-amino-5-hydroxymethyl-cyclopentanetriol or “2-acetamido-2-deoxy-1-(6-aminohexyl)amino- β -D-galacto-cyclopentane” 24


^1H NMR (300 MHz, D₂O): compound 24




^{13}C NMR (75.5 MHz, D₂O): compound 24



COSY (D₂O): compound 24




HSQC (D₂O): compound 24




(1*S*,2*R*,3*S*,4*R*,5*R*)-*N*-(6-dansylamino)hexyl-3-acetamido-4-amino-5-hydroxymethyl-cyclopentanetriol or “2-acetamido-2-deoxy-1-(6-dansylaminohexyl)amino- β -D-galacto-cyclopentane” 25


^1H NMR (300 MHz, CD₃OD): compound 25



^{13}C NMR (75.5 MHz, CD₃OD): compound 25



COSY (CD₃OD): compound 25



HSQC (CD₃OD): compound 25

